Salud financiera de hoja de balance de NATCO Pharma
Salud financiera controles de criterios 6/6
NATCO Pharma tiene un patrimonio de accionistas total de ₹52.9B y una deuda total de ₹2.5B, lo que sitúa su ratio deuda-patrimonio en 4.7%. Sus activos y pasivos totales son ₹62.5B y ₹9.6B respectivamente. El BAIT de NATCO Pharma es de ₹14.6B, por lo que su ratio de cobertura de intereses es de -35.9. Tiene efectivo e inversiones a corto plazo que ascienden a ₹12.2B.
Información clave
4.7%
Ratio deuda-patrimonio
₹2.48b
Deuda
| Ratio de cobertura de intereses | -35.9x |
| Efectivo | ₹12.16b |
| Patrimonio | ₹52.94b |
| Total pasivo | ₹9.61b |
| Activos totales | ₹62.54b |
Actualizaciones recientes sobre salud financiera
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden
Nov 30Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 24These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well
Mar 22Recent updates
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 22Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
Feb 16Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden
Nov 30Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 24These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well
Mar 22Should NATCO Pharma Limited (NSE:NATCOPHARM) Be Part Of Your Dividend Portfolio?
Mar 04Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹33.5B) de NATCOPHARM superan a sus pasivos a corto plazo (₹8.8B).
Pasivo a largo plazo: Los activos a corto plazo de NATCOPHARM (₹33.5B) superan a sus pasivos a largo plazo (₹822.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: NATCOPHARM tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de NATCOPHARM ha pasado de 6.5% a 4.7% en los últimos 5 años.
Cobertura de la deuda: La deuda de NATCOPHARM está bien cubierta por el flujo de caja operativo (302.1%).
Cobertura de intereses: NATCOPHARM gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.